Biopharma companies (Amgen, Genentech) have always used isolators — they have the money and the need. But contract research organisations (CROs) and contract manufacturing organisations (CMOs) are the fastest‑growing end‑user segment. The pharmaceutical isolator market research study shows that CROs/CMOs are growing at over 12% CAGR, because drug companies are outsourcing more production. Instead of building their own isolator suites, they hire a CMO that already has them.

What's the advantage? Flexibility. A CMO can switch between different clients' products, using disposable isolator components to avoid cross‑contamination. The pharmaceutical isolator market trends highlight that academic and research institutes are also growing, as universities set up GMP facilities for cell and gene therapy trials.

But CMOs face pressure: clients demand low costs, but isolators are expensive to operate. That's why some CMOs cut corners — reusing filters too long, skipping validation steps. That's dangerous.

The message: if you're a CMO, invest in quality. If you're a biotech outsourcing production, audit your CMO's isolator practices. Your patients deserve safety.